 This is a comparative study of vonoprazan TAK-438 10 mg or 20 mg in participants in whom endoscopic healing of erosive esophagitis has been confirmed with vonoprazan or adequate treatment with a proton pump inhibitor PPI, to demonstrate the non-inferiority of vonoprazan to lansoprazole in their maintenance treatment 6 months or 24 weeks as well as to determine the clinically recommended dose for vonoprazan for maintenance therapy in erosive esophagitis. 